Mayo Clinic's Precision Mouse Engineering Core in Minnesota can construct gene-targeted vectors for mice to assist researchers.

Fuse Vectors has raised $5.2 million of funding as it moves closer to commercialising its innovative new approach to ...

The funding will accelerate the development of Fuse's technology platform and pipeline of novel gene therapies. With its breakthrough approach, Fuse Vectors aims to be the universal solution for AAV ...

The global viral vector and plasmid DNA manufacturing market size is calculated at USD 8.66 billion in 2025 and is expected ...

New gene therapy for maple syrup urine disease shows promise in preventing deadly symptoms in cows and offers hope for patients.

AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...

The Global Viral Vector Market was valued at approximately USD 3.10 billion in 2022 and is projected to grow at a robust CAGR of more than 11.5% during the forecast period 2023-2030. Read the Market ...

The global Gene Therapy market, valued at US$7.21 billion in 2023, is forecasted to grow at a robust CAGR of 19.4%, reaching ...

In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants ...

Researchers from the NIHR Moorfields Biomedical Research Centre and University College London have found that gene therapy improved visual acuity and preserved retinal structure in young children with ...